ENLV
|Enlivex Therapeutics Ltd
NASDAQ
USD 0.97
+0.05|+5.15%
Current Price
USD 0.97
Change
+USD 0.05 (5.15%)
P/E Ratio
Dividend Yield
Market Cap
23.73M
Volume
57,603
Open
USD 0.93
Previous Close
USD 0.92
52-Week High
USD 1.76
52-Week Low
USD 0.81
About Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat ...
Sector:Healthcare
Industry:Biotechnology
CEO:
Employees:
Headquarters:Ness Ziona, Israel
Website:www.enlivex.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions